On Monday, Stifel altered its stance on Alector Inc . (NASDAQ:ALEC), downgrading the stock from Buy to Hold and adjusting the price target to $4.00. The stock, currently trading near its 52-week low of $1.92, has declined over 75% in the past year.
According to InvestingPro data, the company holds more cash than debt but is quickly burning through its reserves. The revision follows a comprehensive analysis within Stifel's Biotechnology Outlook, which scrutinized controversies and management strategies for 26 companies under their coverage.
The report by Stifel provides an in-depth look at various investment debates surrounding companies like BioMarin Pharmaceutical (NASDAQ:BMRN) Inc., Biogen Inc (NASDAQ:BIIB)., and others. It also forecasts revenue up to the year 2025 for firms nearing significant product launch milestones, including Neurocrine (NASDAQ:NBIX) Biosciences Inc., Acadia Pharmaceuticals Inc., and several more. InvestingPro analysis reveals that Alector's revenue is expected to decline this year, with five analysts recently revising their earnings expectations downward.
In addition to Alector, Stifel downgraded Biogen Inc. (BIIB) to Hold. The firm, however, took a positive turn on Denali Therapeutics Inc. (NASDAQ:DNLI), upgrading it to Buy. The changes reflect Stifel's latest findings from refreshed diligence on the companies within their biotechnology coverage universe.
The outlook also anticipates clinical catalysts for a range of companies, including Alkermes (NASDAQ:ALKS) plc, Lexeo Therapeutics, and many others, indicating a busy period ahead for investors and management teams alike.
Stifel's report emphasizes the importance of upcoming investor conferences in the first quarter, where key questions for management teams across the biotechnology sector will be addressed, potentially influencing the future direction of these companies and their stock performance.
In other recent news, Alector Inc. experienced a significant setback as its Phase 2 INVOKE-2 clinical trial for Alzheimer's disease treatment AL002 failed to meet its primary endpoint, leading to the discontinuation of the program.
In response, Morgan Stanley (NYSE:MS) downgraded Alector's stock from Equalweight to Underweight, slashing its price target to $3.00 from $10.00. However, H.C. Wainwright maintains a Buy rating for the company, albeit with a reduced price target of $7, down from $35, while Goldman Sachs (NYSE:GS) reaffirmed its Sell rating with a price target of $4.
Following the trial's failure, Alector announced plans to reduce its workforce by approximately 17% and to focus on other therapies aimed at neurodegenerative diseases. The company's next major milestone is the Phase 3 INFRONT3 data expected to be released in late 2025 to early 2026.
Alector secured a $50 million credit facility from Hercules Capital (NYSE:HTGC) Inc., aimed at supporting ongoing research and development efforts. The company continues to focus on its other programs, including the PGRN program and five early-stage programs based on their ABC transport technology.
In terms of governance, shareholders elected Louis J. Lavigne, Jr., Richard H. Scheller, Ph.D., and Mark Altmeyer as Class III directors, while Ernst & Young LLP was ratified as the independent accounting firm. As of September 30, 2024, Alector reported having $457.2 million in cash, cash equivalents, and investments, projecting a financial runway through 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.